Request Demo
Pfizer pours $25M investment into Caribou's cell therapies
06 Jul 2023
Cell TherapyFast TrackPhase 1ImmunotherapyGene Therapy
Pfizer is encouraged by Caribou Biosciences' CRISPR hybrid RNA-DNA guides gene editing tech dubbed chRDNAs.
Pfizer is backing CariboCaribou Biosciencesa $25 million equity investment, money the genome editing company will pour into its allogeneic CAR-T cell therapy for multiple myeloma.
Pfizer purchased 4Caribou Biosciencesf Caribou common stock at $5.33 per share in a deal that added up to $25 million and closed June 30. CCAR-T cellich boasts a multiple myelomathe-shelf cell therapies from its CAR-T and CAR-NK platforms, had $291 million in cash, cash equivalents and marketable securities as of March 31.
Pfizerlifornia-based biotech will funneCaribouew money into CB-011, its allogeneic CAR-T cell therapy being studied in a phase 1 clinical Cariboun patients with relapsed or refractory multiple myeloma. The asset, which has secured fast-track designation from the FDA, is one of the first allogeneic CAR-T cell therapies to enter the clinic that is engineered to improve anti-tumor activity through an immune cloaking strategy, according to Caribou. The therapy targets the B-cell maturation antigen and is designed to remove the B2M protein and insert a B2M-HLA-E fusion protein that prevents immune-mediated rejection.
Pfizer is encouraged by Caribou’s CRISPR hybrid RNA-DNA guidCB-011e editing tech—dubbed chRDNAs—and the potential allogeneic cell therapies have as off-the-shelfrelapsed or refractory multiple myelomarelapsed or refractory multiple myeloma, Ph.D., Pfizer’s vice president and development head for multiFDA myeloma and global product develCAR-T cellid in a July 6 release. In connection with the equity investment, tumornaswami is also joining Caribou’s scientific advisory board.B-cell maturation antigenB2M protein
Pfizeru has a lot to proCaribou its phase 1 trial ANTLER study for CB-010, which has enrolled patients with relapsed or refractory B cell non-Hodgkin lymphoma. Lacancerr, just weeks after celebrating a 100% ovPfizerresponse rate, the biotech revealed that 50multiple myelomalapsed within six months of receiving its lead allogeneic CAR-T.Caribou
Durability is a widespread issue for allogeneic CAR-T developers. ICB-010ttempt to tackle CAR-T cell exhaustrelapsed or refractory B cell non-Hodgkin lymphomanger time, Caribou had removed the PD-1 receptors from its anti-CD19 candidate CB-010. However, last year’s results raise questions about the impact of the work to boost durability.
Based on the data, Caribou started enrolling patients at the second dose level, 80 million CAR-T cells. Doubling the dose could drive longer-lasting responses, enabling Caribou to differentiate itself from the rest of the allogeneic CAR-T space and renew confidence in its durability approach.
To date, CB-010 has garnered regenerative medicine advanced therapy, fast-track and orphan CAR-T cellshe FDA. Within the next six months, Caribou plans to share six-month dose escalation data on the candidate, Caribou CEO Rachel Haurwitz, Ph.D., said in the company’s release.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.